These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17468871)

  • 1. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Lee DH; Kim HT; Han JY; Lee SY; Yoon SJ; Kim HY; Lee JS
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):83-8. PubMed ID: 17468871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
    Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
    Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
    Ilson DH; Saltz L; Enzinger P; Huang Y; Kornblith A; Gollub M; O'Reilly E; Schwartz G; DeGroff J; Gonzalez G; Kelsen DP
    J Clin Oncol; 1999 Oct; 17(10):3270-5. PubMed ID: 10506629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck.
    Gilbert J; Cmelak A; Shyr Y; Netterville J; Burkey BB; Sinard RJ; Yarbrough WG; Chung CH; Aulino JM; Murphy BA
    Cancer; 2008 Jul; 113(1):186-92. PubMed ID: 18484593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.
    Kim M; Keam B; Kim TM; Kim HG; Kim JS; Lee SS; Shin SH; Kim MK; Park KU; Kim DW; Yun HJ; Lee JS; Heo DS
    Cancer Res Treat; 2017 Apr; 49(2):416-422. PubMed ID: 27488873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J; Xu X; Wang F; Yan G; Liu J; Lu W; Li X; Tucker SJ; Zhong B; Cao Z; Wang D
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
    Lordick F; von Schilling C; Bernhard H; Hennig M; Bredenkamp R; Peschel C
    Br J Cancer; 2003 Aug; 89(4):630-3. PubMed ID: 12915869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
    Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
    Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Muggia FM; Blessing JA; McGehee R; Monk BJ
    Gynecol Oncol; 2004 Aug; 94(2):483-7. PubMed ID: 15297192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.